Bicara presents survival data for ficerafusp alfa + Keytruda in head/neck cancer: 21.3 months median OS, 46% 2-year OS rate ...

AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

Sanofi and Regeneron on Friday reported lackluster late-stage results for their drug candidate in a common lung condition, ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement ...

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...